Albemarle Corp ALB
We take great care to ensure that the data presented and summarized in this overview for ALBEMARLE CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALB
View all-
Vanguard Group Inc Valley Forge, PA14.1MShares$1.85 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY9.91MShares$1.3 Billion0.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.92MShares$907 Million0.21% of portfolio
-
State Street Corp Boston, MA5.93MShares$778 Million0.04% of portfolio
-
Franklin Resources Inc San Mateo, CA5.68MShares$745 Million0.25% of portfolio
-
Primecap Management CO Pasadena, CA3.73MShares$488 Million0.37% of portfolio
-
Geode Capital Management, LLC Boston, MA2.69MShares$352 Million0.03% of portfolio
-
Baillie Gifford & CO2.47MShares$324 Million0.26% of portfolio
-
Invesco Ltd. Atlanta, GA2.08MShares$273 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA1.94MShares$254 Million0.05% of portfolio
Latest Institutional Activity in ALB
Top Purchases
Top Sells
About ALB
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes in the areas of steroid chemistry and vitamins, life sciences, pharmaceutical industry, and other markets. It also provides cesium products for the chemical and pharmaceutical industries; zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Bromine segment offers bromine and bromine-based fire safety solutions; specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals for use in chemical synthesis, oil and gas well drilling and completion fluids, mercury control, water purification, beef and poultry processing, and other industrial applications; and other specialty chemicals, such as tertiary amines for surfactants, biocides, and disinfectants and sanitizers. The Catalysts segment provides hydroprocessing, isomerization, and akylation catalysts; fluidized catalytic cracking catalysts and additives; and organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.
Insider Transactions at ALB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 14
2024
|
Mark Richard Mummert SVP, Capital Projects |
SELL
Open market or private sale
|
Direct |
843
-11.03%
|
$113,805
$135.53 P/Share
|
May 13
2024
|
John Clarence Barichivich Iii VP, Controller & CAO |
SELL
Open market or private sale
|
Direct |
1,475
-23.72%
|
$194,700
$132.17 P/Share
|
Feb 28
2024
|
Netha N. Johnson President, Specialties |
SELL
Payment of exercise price or tax liability
|
Direct |
743
-2.31%
|
$98,076
$132.06 P/Share
|
Feb 28
2024
|
Netha N. Johnson President, Specialties |
BUY
Exercise of conversion of derivative security
|
Direct |
1,680
+4.96%
|
-
|
Feb 28
2024
|
Eric Norris President, Energy Storage |
SELL
Payment of exercise price or tax liability
|
Direct |
743
-2.09%
|
$98,076
$132.06 P/Share
|
Feb 28
2024
|
Eric Norris President, Energy Storage |
BUY
Exercise of conversion of derivative security
|
Direct |
1,680
+4.51%
|
-
|
Feb 28
2024
|
John Clarence Barichivich Iii VP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
157
-2.46%
|
$20,724
$132.06 P/Share
|
Feb 28
2024
|
John Clarence Barichivich Iii VP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
535
+7.74%
|
-
|
Feb 28
2024
|
Jacobus G. Fourie Chief Capital Projects Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
406
-2.4%
|
$53,592
$132.06 P/Share
|
Feb 28
2024
|
Jacobus G. Fourie Chief Capital Projects Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
917
+5.14%
|
-
|
Feb 26
2024
|
Kristin M. Coleman EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
543
-17.32%
|
$65,703
$121.52 P/Share
|
Feb 26
2024
|
Kristin M. Coleman EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
1,763
+35.99%
|
-
|
Feb 26
2024
|
Neal Ravi Sheorey EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
151
-49.67%
|
$18,271
$121.52 P/Share
|
Feb 26
2024
|
Neal Ravi Sheorey EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
304
+50.0%
|
-
|
Feb 26
2024
|
Netha N. Johnson President, Specialties |
SELL
Payment of exercise price or tax liability
|
Direct |
921
-1.5%
|
$111,441
$121.52 P/Share
|
Feb 26
2024
|
Netha N. Johnson President, Specialties |
BUY
Exercise of conversion of derivative security
|
Direct |
875
+2.76%
|
-
|
Feb 26
2024
|
Netha N. Johnson President, Specialties |
BUY
Grant, award, or other acquisition
|
Direct |
1,206
+3.8%
|
-
|
Feb 26
2024
|
Jacobus G. Fourie Chief Capital Projects Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
627
-1.94%
|
$75,867
$121.52 P/Share
|
Feb 26
2024
|
Jacobus G. Fourie Chief Capital Projects Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
478
+2.88%
|
-
|
Feb 26
2024
|
Jacobus G. Fourie Chief Capital Projects Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,665
+9.34%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 21.5K shares |
---|---|
Exercise of conversion of derivative security | 69.5K shares |
Open market or private purchase | 1.37K shares |
Payment of exercise price or tax liability | 32.9K shares |
---|---|
Open market or private sale | 2.32K shares |